Pharmexon is excited to announce our expansion into new territories

GRAND NEWS: Pharmexon is excited to announce our expansion into new territories, including the Balkans, Turkey, Ukraine, CIS, UAE, South Africa, and Jordan. This growth allows us to provide comprehensive regulatory affairs and pharmacovigilance services across these regions, including complex expert support with the development, submission, and lifecycle of medicines, medical devices, and food supplements. Global market expansion has always been a top priority for Pharmexon, and we are thrilled to extend our reach and support our clients in these new areas.

Our unique strength lies in our ability to integrate knowledge from agencies, industry, and consultancy. By leveraging this invaluable experience, we are able to help our clients elevate their businesses to new heights.
Our full support now extends to the US, Canada, EU, UK, Switzerland, Balkans, Turkey, Ukraine, CIS, Russia, UAE, Jordan, South Africa, Australia, New Zealand, and the Philippines.

If you need our assistance in these global markets, we are here to help. Please contact BDinquiries@pharmexon.com for more information.

Latest Posts
๐Ÿ“š Strengthening Our Expertise: Product-Specific Guidance

At Pharmexon, we believe in fostering a culture of continuous learning to stay ahead in

Regulatory Intelligence September – October 2024

The Pharmaceutical Industry is incredibly dynamic, with constant updates occurring all through various fields encompassing

๐Ÿšจ Important Update from the European Medicines Agency (EMA) ๐Ÿšจ

This fall a significant EMA update of guideline on Environmental Risk Assessment (ERA) for Medicinal

Pharmexon Company Breakfast

Only a couple of weeks ago, one of Pharmexonโ€™s favorite traditions occurredโ€” the Pharmexon Company

๐—ฃ๐—ต๐—ฎ๐—ฟ๐—บ๐—ฒ๐˜…๐—ผ๐—ป ๐—ต๐—ฎ๐—ฑ ๐˜๐—ต๐—ฒ ๐—ฝ๐—น๐—ฒ๐—ฎ๐˜€๐˜‚๐—ฟ๐—ฒ ๐—ผ๐—ณ ๐—ฎ๐˜๐˜๐—ฒ๐—ป๐—ฑ๐—ถ๐—ป๐—ด BioBridges Conference ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฐ ๐—ถ๐—ป ๐—ฃ๐—ฟ๐—ฎ๐—ด๐˜‚๐—ฒ!

From September 26th to 27th, the event brought together professionals in bioequivalence and pharmaceutical development,